Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?

Core Insights - Zacks Premium provides tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1][9] Zacks Style Scores - Zacks Style Scores are indicators that help investors select stocks likely to outperform the market in the next 30 days, rated from A to F based on value, growth, and momentum [2] - The Value Score identifies attractive and discounted stocks using ratios like P/E and Price/Sales [3] - The Growth Score focuses on a company's financial health and future outlook, analyzing projected earnings and cash flow [4] - The Momentum Score capitalizes on price trends, using factors like weekly price changes to identify high-momentum stocks [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for stock selection [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, outperforming the S&P 500 [7][8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [10] Teva Pharmaceutical Industries Ltd. - Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company based in Tel Aviv, Israel, focusing on branded and generic drugs, including biosimilars and OTC products [12] - Teva holds a Zacks Rank of 3 (Hold) with a VGM Score of A and a Momentum Style Score of B, having seen a 17.3% increase in shares over the past four weeks [13] - Recent upward revisions in earnings estimates for fiscal 2025 have increased the Zacks Consensus Estimate by $0.01 to $2.55 per share, with an average earnings surprise of 2.2% [13][14]